Merck & Co., Inc.

NYSE:MRK

Drug Manufacturers - General

Healthcare
$137.78 -1.14%

-$1.32 today

Market cap
$339.66B
Beta
0.22
P/E (TTM)
31.6
EPS (TTM)
$3.61
Dividend yield
2.94%
52W Low $76.66High $125.14

Volume 9.69M

Average 11.85M

MRK Common Stock Repurchased

Cash spent buying back the company's own shares.

Merck & Co., Inc.NYSE: MRK

Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026

Common stock repurchased dips below year-ago levels

Q2 FY2026 common stock repurchased of $757M (cash outflow) fell 43.7% year over year, behind the +22.2% change in trailing-twelve-month common stock repurchased. Sequentially, it fell 13.4% from the prior quarter.

Context

  • Common stock repurchased amounted to 7.8% of revenue in FY2025, up 5.8 pp from a year earlier.
  • Common stock repurchased increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -43.7% toward the trailing-twelve-month pace of +22.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$757M-13.4% QoQ
Last fiscal yearDec 2025
-$5.08B+289.3% YoY
LTMJun 2026
-$4.21B+22.2% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.7%——
1 year+289.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
(5.08B) USD
Year-over-year change
-289.3%

Common Stock Repurchased vs competitors

How MRK compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +22.2% is the 5th highest of 8, against a peer median of +40.5%.
  • Common stock repurchased amounts to 6.3% of revenue for MRK, versus a peer median of 2.5%.
MRK Competitors
Common Stock Repurchased for MRK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$7.88B USD+82.8%-0.5%7.9%
NVSNovartis AGLTM Jun 2026$6.85B USD-38.0%-4.6%12.3%
LLYEli Lilly and CompanyLTM Jun 2026$6.17B USD+40.5%+39.9%7.7%
MRKMerck & Co., Inc.LTM Jun 2026$4.21B USD+22.2%—6.3%
ABBVAbbVie Inc.LTM Jun 2026$1.51B USD+11.6%-13.0%2.3%
GILDGilead Sciences, Inc.LTM Jun 2026$1.44B USD-24.5%+11.2%4.7%
SNYSanofiLTM Jun 2026€1.21B EUR—+125.2%2.5%
AZNAstraZeneca PLCLTM Sep 2026$348.8M USD+2624.7%—0.6%
AMGNAmgen Inc.LTM Jun 2026$0 USD+100.0%—0.0%
PFEPfizer Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding MRK) —+40.5%+5.4%2.5%

Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income12.36B14.53B365M17.13B18.25B
Depreciation & Amortization3.21B3.91B3.87B4.5B5.84B
Deferred Income Tax187M(1.57B)(1.9B)(1.25B)(1.67B)
Stock-Based Compensation479M541M645M761M0
Change in Working Capital(3.84B)(2.78B)(2.21B)(3.67B)(6.98B)
Accounts Receivables(2.03B)(644M)(1.15B)(244M)(1.09B)
Inventory(674M)(161M)(816M)(835M)(1.18B)
Accounts Payables405M(289M)(380M)182M110M
Other Working Capital(1.54B)(1.69B)139M(2.77B)(4.82B)
Other Non-Cash Items1.71B4.47B12.23B3.99B1.03B
Operating Cash Flow14.11B19.1B13.01B21.47B16.47B
Capital Expenditures(4.45B)(4.39B)(3.86B)(3.37B)(4.11B)
Acquisitions (Net)(12.91B)(121M)(12.03B)(4.09B)(10.04B)
Purchases of Investments(1M)(1.2B)(955M)(519M)(1.21B)
Sales of Investments1.03B721M1.66B377M1.68B
Other Investing Activities(225M)32M1.11B(127M)(58M)
Investing Cash Flow(16.56B)(4.96B)(14.08B)(7.73B)(13.74B)
Debt Repayment1.63B(2.25B)4.18B2.31B11.38B
Common Stock Issued0384M0092M
Common Stock Repurchased(840M)0(1.35B)(1.31B)(5.08B)
Dividends Paid(6.61B)(7.01B)(7.45B)(7.84B)(8.18B)
Other Financing Activities8.41B(240M)(203M)(195M)(131M)
Financing Cash Flow2.59B(9.12B)(4.81B)(7.03B)(1.92B)
Effect of Forex Changes(133M)(410M)23M(293M)563M
Net Change in Cash14M4.61B(5.86B)6.41B1.37B
Free Cash Flow9.66B14.71B9.14B18.1B12.36B

Merck & Co., Inc.

NYSE:MRK

Intrinsic Alpha fair value

Locked

Current Price

$137.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.